PASADENA, Calif. , August 12, 2024 – AcuraStem, a patient-based biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, announced today that CEO Sam Alworth has been invited to speak at the RNA Leaders USA Congress, scheduled for September 4-5, 2024, at the San Diego Convention Center.
The RNA Leaders USA Congress brings together the brightest minds in biotech and serves as a pivotal platform for discussing the latest advancements in Ribonucleic acid (RNA) technology, with a focus on mRNA, RNAi, antisense oligonucleotides (ASOs), oligonucleotides, vaccines, microRNAs, genome editing, and broader nucleic acids & RNA targets. The conference attracts leading figures from biotechnology, pharmaceuticals, and academic research, fostering discussions on innovative therapies and collaboration among experts in the field.
During his talk, Alworth will explore the transformative potential of RNA therapeutics in neurodegenerative disease research and focus on the groundbreaking capabilities of AcuraStem’s iNeuroRx® platform. He will also highlight two of AcuraStem’s key ALS programs targeting the UNC13A and SYF2 genes.
"Speaking at the RNA Leaders USA Congress is a tremendous opportunity to highlight the impact of RNA therapeutics in neurodegenerative diseases,” said Alworth. “Our work at AcuraStem is at the forefront of developing more effective treatments that not only address symptoms but also fundamentally alter disease progression. I look forward to sharing our progress and engaging with other leaders in the field to push the boundaries of what’s possible in drug discovery."
AcuraStem is dedicated to advancing neurodegenerative diseases research through its iNeuroRx® platform, which enables the discovery of innovative, effective, and broadly acting treatments. Mr. Alworth’s participation in this important industry event provides a valuable opportunity to showcase AcuraStem’s progress in developing groundbreaking therapies for neurodegenerative diseases and transitioning these innovations from the laboratory to the clinic.
For more information about AcuraStem’s pioneering work, please visit acurastem.com
For more information about the RNA Leaders USA Congress, please visit https://informaconnect.com/rna-leaders/.
About AcuraStem
AcuraStem is a patient-based biotechnology company pioneering treatments for neurodegenerative diseases including sporadic ALS and FTD. AcuraStem’s best-in-class disease modeling platform, iNeuroRx®, enables the discovery of innovative, effective, and broadly acting treatments. The team’s strong expertise in ASO technology provides for the rapid advancement of treatments to the clinic. AcuraStem’s research is funded in part by support from the Alzheimer’s Drug Discovery Foundation, Harrington Discovery Institute, Alzheimer’s Association, Rainwater Charitable Foundation, Department of Defense and the National Institutes of Health.
Contact:
Kissy Black
Director of Communications, AcuraStem
kblack@acurastem.com
615.310.1894